Mon panier

Canine CD20 / MS4A1 Full Length Protein, His Tag (Detergent)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Qté
CD0-C52H5-20ug
$805.00
CD0-C52H5-100ug
$2985.00
CD0-C52H5-500ug
$7480.00
ETA of in-stock products:2 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Application

    1. Immunization
    2. Affinity testing (SPR / BLI)
    3. Screening (ELISA)
  • Synonyms

    MS4A1, CD20, MS4A-1

  • Source

    Detergent Canine CD20 Full Length, His Tag (CD0-C52H5) is expressed from human 293 cells (HEK293). It contains AA Met 1 - Pro 297 (Accession # Q3C2E2-1).

    Predicted N-terminus: Met 1

    Request for sequence
  • Molecular Characterization

    CD20 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 35.2 kDa. The protein migrates as 40 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

    *The DDM/CHS buffer (Cat. No. DC-11) is sold separately and not included in protein, you can follow the link for product information.

    1. Structure

      Each full-length transmembrane protein is encapsulated by detergent micelle.

    2. Synthesis Process

      Through mild detergent micelle extraction, dedicated solubilization, and stringent affinity purification, we maximally retain the native transmembrane conformation of full-length transmembrane proteins throughout downstream purification. This workflow yields purified, detergent-solubilized proteins free of unrelated membrane impurities and exogenous scaffold proteins, with exceptional purity, accurate quantitation, and well-preserved biological activity—ideal for immunization, binding assays in antibody discovery and screening (ELISA) and affinity testing (SPR and BLI), etc.

  • Endotoxin

    Less than 1.0 EU per μg by the LAL method / rFC method.

  • Purity

    >80% as determined by SDS-PAGE.

  • Formulation

    This product is not suitable for cell based experiments due to cytotoxicity of DDM.
    DDM and CHS are INDISPENSABLE to keep membrane protein soluble and active, under no circumstances should you remove DDM and CHS.
    DDM/CHS buffer (DC-11) is sold separately and not included in protein, and please contact us if you need the buffer.
    If glycerol is not compatible with your application, remove glycerol just before the immediate experiment, and NEVER store glycerol-free protein solution.

    Supplied as 0.2 μm filtered solution in 50 mM HEPES, 150 mM NaCl, DDM, CHS, pH7.5 with glycerol as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. The product MUST be stored at -70°C or lower upon receipt;
    2. -70°C for 3 months under sterile conditions.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    CD20 SDS-PAGE

    Canine CD20 Full Length, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 80%.

  • Bioactivity-ELISA

     CD20 ELISA

    Immobilized Canine CD20 Full Length, His Tag (Cat. No. CD0-C52H5) at 5 μg/mL (100 μL/well) can bind Rabbit Anti-CD20 antibody with a linear range of 1-78 ng/mL (QC tested).

    Protocol
  • Bioactivity-SPR

     CD20 SPR

    Rabbit anti-Human CD20 Antibody captured on Protein G Chip can bind Canine CD20 Full Length, His Tag (Cat. No. CD0-C52H5) with an affinity constant of 4.77 nM as determined in a SPR assay (in presence of DDM and CHS) (Biacore 8K) (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

Introduction de fond

A B-lymphocyte surface antigen expressed from pre-B to mature B cells, but absent on plasma cells. It functions as a calcium channel and is a validated immunotherapy target, famously exploited by rituximab for treating B-cell malignancies and autoimmune disorders.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    B-lymphocyte antigen CD20

  • Catégorie:

  • Nombre de médicaments répertoriés:

    35 Détails

  • Nombre de médicaments cliniques:

    132 Détails

  • Étape de développement la plus élevée:

    Approved

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • Contexte